(FM) Oncología

2021

1. 10-Year Results of a Phase III Randomized Trial of High-Dose Radiotherapy and Risk-Adapted Androgen Deprivation in Localized Prostate Cancer

   International journal of radiation oncology, biology, physics, Vol. 111, Núm. 3, pp. S77

2. A CT-based radiomics signature is associated with response to immune checkpoint inhibitors in advanced solid tumors

   Radiology, Vol. 299, Núm. 1, pp. 109-119

3. A burned-out cd8+ t-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy

   Cancer Discovery, Vol. 11, Núm. 7, pp. 1700-1715

4. A method using 4D dose accumulation to quantify the interplay effect in lung stereotactic body radiation therapy

   Physics in Medicine and Biology, Vol. 66, Núm. 3

5. A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer

   Translational Research, Vol. 233, pp. 77-91

6. A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment

   Clinical and Translational Oncology, Vol. 23, Núm. 3, pp. 434-449

7. A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial

   International Journal of Gynecological Cancer, Vol. 31, Núm. 4, pp. 617-622

8. A proteomic atlas of lineage and cancer-polarized expression modules in myeloid cells modeling immunosuppressive tumor-infiltrating subsets

   Journal of Personalized Medicine, Vol. 11, Núm. 6

9. Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic

   Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Núm. 26

10. Association of the lung immune prognostic index with immunotherapy outcomes in mismatch repair deficient tumors

    Cancers, Vol. 13, Núm. 15

11. Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies

    Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 882-891

12. Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?

    Clinical and Translational Oncology, Vol. 23, Núm. 3, pp. 536-542

13. Body shape trajectories and risk of breast cancer: Results from the SUN ('Seguimiento Universidad de Navarra') Project

    Public Health Nutrition, Vol. 24, Núm. 3, pp. 467-475

14. CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation

    Nature Communications, Vol. 12, Núm. 1

15. Cancer survivors referred to a long-term survivorship outpatient service within academic medical oncology: descriptive study

    Journal of Cancer Survivorship, Vol. 15, Núm. 6, pp. 811-817

16. Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial

    ESMO Open, Vol. 6, Núm. 2

17. Challenges and novel opportunities of radiation therapy for brain metastases in non-small cell lung cancer

    Cancers, Vol. 13, Núm. 9

18. Characterization of the perioperative changes of exosomal immune-related cytokines induced by prostatectomy in early-stage prostate cancer patients

    Cytokine, Vol. 141

19. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

    European Journal of Cancer, Vol. 152, pp. 68-77

20. Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma

    Virchows Archiv, Vol. 479, Núm. 6, pp. 1167-1176